Finerenone FDA Approval Status
FDA Approved: No
Generic name: finerenone
Company: Bayer HealthCare Pharmaceuticals Inc.
Treatment for: Chronic Kidney Disease and Type 2 Diabetes
Finerenone (BAY 94-8862) is an investigational, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) in development for use in patients with chronic kidney disease and type 2 diabetes.Finerenone has been shown to reduce many of the harmful effects of mineralocorticoid receptor (MR) overactivation, which is a driver of kidney and cardiovascular damage through inflammatory and fibrotic processes.
Development Timeline for finerenone
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.